| RAS GTPase family inhibitor being developed by Amgen for the treatment of KRAS G12C-mutated NSCLC |
| Received its first approval on 28 May 2021 in the USA |
| Approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.